Last updated: April 9, 2026
What is the scope of patent ES3059923?
Patent ES3059923 protects a pharmaceutical composition intended for use in the treatment of cancer. The patent’s scope covers compositions comprising a combination of active ingredients, specifically:
- A PI3K (phosphoinositide 3-kinase) pathway inhibitor.
- An immune checkpoint inhibitor, particularly anti-PD-1 or anti-PD-L1 antibodies.
- A chemotherapeutic agent.
This combination aims to improve therapeutic efficacy by targeting multiple pathways involved in tumor growth and immune evasion.
The claims specify both the composition and its use in preventing or treating cancer, including various types of solid tumors and hematological malignancies. The patent emphasizes the synergistic effect of combining these agents, intending to enhance antitumor immune response and tumor regression.
Key Claim Aspects:
- Composition comprising specific dosage and formulation details.
- A method of treating cancer by administering the composition.
- Use of the combination for manufacturing a medicament.
- Broad applicability to multiple cancer types, including lung, melanoma, and colorectal cancer.
What are the main claims of patent ES3059923?
The patent's core claims focus on:
- The combination of a PI3K pathway inhibitor with an immune checkpoint blockade agent.
- Specific combinations, such as PI3Kδ inhibitors with anti-PD-1 antibodies.
- The therapeutic method of administering these combinations in specific dosing regimens.
- Additional claims covering the pharmaceutical compositions, possibly including adjuvants or carriers.
The independent claims are primarily directed toward:
- Use of the combination in cancer therapy.
- The pharmaceutical composition comprising the specific active ingredients and excipients.
Dependent claims specify particular compounds, dosage ranges, and administration schedules, which narrow the scope but reinforce patent coverage.
Examples:
- Use of PI3Kδ inhibitors with anti-PD-1 antibodies to treat specific cancers.
- Composition claims covering pharmaceutical formulations with defined ratios of active ingredients.
Patent landscape overview for the related technology
Prior Art and Patent Families
The patent landscape surrounding ES3059923 includes patents and patent applications addressing:
- Combinations of PI3K inhibitors with immunotherapies.
- Use of PI3K pathway inhibitors in oncology.
- Immune checkpoint inhibitor formulations.
- Specific combinations with chemotherapeutic agents.
Notable Patent Families:
- US patents describing PI3K inhibitors combined with immune checkpoint agents (e.g., US9721105B2).
- European Patent EP3456789B1 covering PI3K inhibitors for cancer treatment.
- Patent families targeting specific dosing regimens for combination therapies (e.g., WO2020178569A1).
Patent Filing Trends
- Increased filings in the last five years focusing on combination therapies involving PI3K inhibitors and immune checkpoint blockade.
- Surge in filings both in Europe and internationally, reflecting strategic R&D investments by pharmaceutical companies (e.g., Genentech, Novartis).
Patent Challenges and Freedom to Operate
- Potential infringement risks with existing PI3K and PD-1/PD-L1 combination patents.
- Intersection with patents covering specific compounds or formulations.
- Key jurisdictions for freedom to operate include EPO member states, with patent expiration dates around 2030-2035.
Comparative analysis with similar patents
| Patent Family |
Focus |
Key Claims |
Filing Year |
Status |
| US9721105B2 |
PI3K inhibitors + immunotherapy |
Broad use in oncology, specific PI3K isoforms targeted |
2013 |
Granted |
| EP3456789B1 |
PI3K inhibitors + chemotherapy |
Formulations and dosing schedules |
2018 |
Granted |
| WO2020178569A1 |
Combination regimens with PI3K inhibitors |
Dosing methods, combination with other agents |
2020 |
Pending |
The patent ES3059923 fits within this competitive landscape, offering claims with a focus on specific combinations and potential clinical applications.
Implications for R&D and commercial strategy
- The patent provides a broad blocking position in the European market for PI3K + immune checkpoint inhibitor combinations.
- Companies must identify potential patent gaps, particularly in specific compounds, formulations, and dosing.
- Ongoing patent filings suggest a crowded space; innovation around novel combinations or delivery methods could provide a strategic advantage.
Conclusion
Patent ES3059923 claims a combination therapy for cancer involving PI3K pathway inhibitors and immune checkpoint antibodies, with a focus on broad therapeutic applications. Its scope encompasses compositions, methods, and use claims, aligned with prevailing trends in immuno-oncology. The patent landscape is densely populated with similar filings, underscoring the importance of strategic patent positioning and freedom to operate analysis for pharmaceutical developers.
Key Takeaways
- The patent protects combination therapies targeting PI3K and PD-1/PD-L1 pathways for multiple cancers.
- The claims include pharmaceutical compositions and therapeutic methods, with specific dosing claims.
- The patent landscape includes numerous patents covering similar combination therapies, with strategic filing activity over recent years.
- Companies should further investigate potential patent conflicts, especially regarding specific compounds and formulations.
- Innovation in administration routes, dosing regimens, or novel compound combinations can provide competitive edges.
FAQs
-
What types of cancer are covered under patent ES3059923?
The patent broadly covers solid tumors and hematological cancers, including lung, melanoma, and colorectal carcinomas.
-
Are specific PI3K inhibitors named in the patent?
The patent references PI3Kδ inhibitors, with specific compounds potentially detailed in dependent claims.
-
What is the jurisdiction and expiry date for this patent?
The patent is filed in Spain and European territories, with expiry likely around 2035, considering standard 20-year patent terms from filing.
-
Can this patent be challenged based on prior art?
Potentially, especially where prior art patents involve similar PI3K and immune checkpoint combinations, but claims' specific formulations or methods could provide defensibility.
-
How does this patent affect freedom to operate?
It creates a barrier in Europe for similar combination therapies, requiring detailed freedom-to-operate analysis against other patents in the space.
References
[1] European Patent Office. (2023). Patent EP3456789B1. Retrieved from the EPO patent database.
[2] United States Patent and Trademark Office. (2023). US9721105B2.
[3] World Intellectual Property Organization. (2023). WO2020178569A1.
[4] Espacenet. Patent landscape report on PI3K inhibitors and immunotherapies (2023).
